Syndopa 275 is not advocated in individuals hypersensitive to its ingredients, narrow-angle glaucoma, suspicious, undiagnosed skin lesion or a history of melanoma (since levodopa is known to activate a malignant melanoma), nursing mothers and in those taking monoamine oxidase inhibitors.